Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Invasive candidiasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Invasive candidiasis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-006409-18 Sponsor Protocol Number: 9463-EC-0002 Start Date*: 2010-02-09
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, D...
    Medical condition: Invasive Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007152 Candidiasis LLT
    12.1 10007162 Candidiasis of the intestine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) HU (Completed) BE (Completed) GR (Completed) DE (Completed) FR (Completed) FI (Completed) IT (Completed) GB (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014600-66 Sponsor Protocol Number: IFN-gamma 001 Start Date*: 2010-08-10
    Sponsor Name:University Medical Center Nijmegen
    Full Title: A multicentre, prospective, randomized open-label pilot study to assess the feasibility and preliminary efficacy of interferon gamma in combination with Anidulafungin for the treatment of candidemia
    Medical condition: Candida bloodstream infections/ candidemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10042938 Systemic candida LLT
    12.1 10042939 Systemic candidiasis LLT
    12.1 10049160 Candidaemia LLT
    12.1 10053166 Candida sepsis PT
    12.1 10060573 Candidemia LLT
    12.1 10013431 Disseminated candidiasis LLT
    12.1 10052240 Septicaemia candida LLT
    12.1 10054610 Septicemia candida LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004504-36 Sponsor Protocol Number: 801-00 Start Date*: 2005-12-20
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.
    Medical condition: Candidiasis (invasive)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10007152 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) IT (Completed) PT (Completed) DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2004-001491-39 Sponsor Protocol Number: 03-0-192 Start Date*: 2005-02-16
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA
    Medical condition: Invasive candidiasis or candidemia
    Disease: Version SOC Term Classification Code Term Level
    7.0 10042938 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) BE (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-015159-26 Sponsor Protocol Number: UKW-Inf-001 Start Date*: 2011-03-14
    Sponsor Name:Universitaetsklinikum Wuerzburg
    Full Title: UKW-Inf-001: Prospective trial to evaluate pharmacokinetic, safety and efficacy of intermittent application of increased doses of caspofungin for antifungal prophylaxis in high risk patients.
    Medical condition: Prophylaxis of invasive fungal infection, including life-threatening aspergillosis and candidiasis, is investigated in the study. Patient with acute myeloid leukemia or acute lymphatic leukemia wil...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003488 Aspergillosis PT
    12.1 10042941 Systemic fungal infection NOS LLT
    12.1 10007152 Candidiasis LLT
    12.1 10036898 Prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012848-16 Sponsor Protocol Number: A1501085 Start Date*: 2010-04-28
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
    Full Title: A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPH...
    Medical condition: Invasive candidiasis, including candidemia (ICC), and esophageal candidiasis (EC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10060573 Candidemia LLT
    14.1 10021881 - Infections and infestations 10064954 Invasive candidiasis LLT
    14.1 10021881 - Infections and infestations 10007161 Candidiasis of the esophagus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) HU (Prematurely Ended) SK (Completed) CZ (Prematurely Ended) BG (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000607-15 Sponsor Protocol Number: GS-IT-131-0177 Start Date*: 2007-12-06
    Sponsor Name:GILEAD SCIENCES S.R.L.
    Full Title: Phase II pilot multicenter study on efficacy and safety of liposomal amphotericin B (AmBisome) at 2 mg/kg/day in the treatment of candidemia and invasive candidiasis in nonneutropenic patients
    Medical condition: CANDIDEMIA AND INVASIVE CANDIDIASIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007134 Candida infections HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016386-28 Sponsor Protocol Number: ANIDULA-133 Start Date*: 2010-01-05
    Sponsor Name:University Medical Center Groningen
    Full Title: Pharmacokinetics of critically ill patients with invasive candidiasis
    Medical condition: invasive candidiasis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064954 Invasive candidiasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000648-32 Sponsor Protocol Number: SCY-078-302 Start Date*: 2023-03-31
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp ver...
    Medical condition: Invasive Candidiasis/ Candidemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10060573 Candidemia LLT
    20.0 10021881 - Infections and infestations 10064954 Invasive candidiasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned) FR (Trial now transitioned) ES (Temporarily Halted) BE (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003793-13 Sponsor Protocol Number: 2017_07 Start Date*: 2018-03-22
    Sponsor Name:centre hospitalier et universitaire de Lille
    Full Title: Arrêt précoce du traitement antifongique empirique en réanimation guidé par dosages sériques de biomarqueurs fongiques : Etude randomisée contrôlée
    Medical condition: INFECTION INVASIVE A CANDIDA
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10049991 Candidal infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004150-32 Sponsor Protocol Number: A8851008 Start Date*: 2008-11-18
    Sponsor Name:Pfizer, Spain
    Full Title: ESTUDIO PROSPECTIVO ABIERTO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE LA ANIDULAFUNGINA EN EL TRATAMIENTO DE NIÑOS Y ADOLESCENTES CON CANDIDIASIS INVASIVA, INCLUIDA LA CANDIDEM...
    Medical condition: CANDIDIASIS INVASIVA, INCLUIDA CANDIDEMIA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) FR (Completed) PT (Completed) IT (Completed) GR (Completed) Outside EU/EEA GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001566-26 Sponsor Protocol Number: BDG-ETHIC Start Date*: 2017-01-11
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: A B-D-GLUCAN DRIVEN ANTIFUNGAL STEWARDSHIP APPROACH TO MANAGE EMPIRICAL THERAPY IN PATIENTS AT VERY HIGH RISK FOR INVASIVE CANDIDIASIS: A RANDOMIZED CONTROLLED TRIAL
    Medical condition: invasive candidiasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10064954 Invasive candidiasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004910-27 Sponsor Protocol Number: MK-0991-074 Start Date*: 2015-02-24
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents with Documented Candida or Asp...
    Medical condition: Candida or Aspergillus Infections
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004854-97 Sponsor Protocol Number: A8851019 Start Date*: 2008-01-15
    Sponsor Name:Pfizer Ltd
    Full Title: OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE...
    Medical condition: CANDIDAEMIA/INVASIVE CANDIDIASIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) BE (Completed) PT (Completed) NL (Completed) IT (Completed) SK (Completed) PL (Completed) CZ (Completed) DK (Completed) HU (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002630-21 Sponsor Protocol Number: CD101.IV.3.05 Start Date*: 2019-01-10
    Sponsor Name:Cidara Therapeutics Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection versus Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the...
    Medical condition: Candidemia; invasive candidiasis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10064954 Invasive candidiasis LLT
    20.0 100000004862 10060573 Candidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DE (Completed) GR (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002084-26 Sponsor Protocol Number: MK0991-064 Start Date*: 2017-01-27
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasiv...
    Medical condition: Invasive Candidiasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10064954 Invasive candidiasis LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-003951-18 Sponsor Protocol Number: WSA-CS-008 Start Date*: 2007-05-29
    Sponsor Name:Astellas Global Pharma Development, Inc.
    Full Title: A phase III, double-blind, randomized study to evaluate the safety and efficacy of BAL8557 versus a Caspofungin followed by Voriconazole regimen in the treatment of candidemia and other invasive Ca...
    Medical condition: Treatment of Candidemia and other invasive Candida infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10060573 Candidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003617-34 Sponsor Protocol Number: 41676 Start Date*: 2013-01-30
    Sponsor Name:University Medical Center Groningen
    Full Title: Pharmacokinetics and optimal dosage of caspofungin in critically ill patients with suspected invasive candidiasis.
    Medical condition: suspected invasive candidiasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000424-32 Sponsor Protocol Number: 045 Start Date*: 2004-09-23
    Sponsor Name:Merck Sharp & Dohme BV
    Full Title: A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in the Treatment of Adults with Invasive Candida Infections (Excluding Patients w...
    Medical condition: Non-Blood Invasive Candidiasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000780-24 Sponsor Protocol Number: 9463-CL-2303 Start Date*: 2012-07-24
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis
    Medical condition: Neonatal Candidiasis
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Nov 05 01:22:17 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA